J2A-MC-GZPO: A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Tablet Once Daily Compared with Placebo in Participants with Obesity or Overweight with and without Type 2 Diabetes. J2A-MC-GZP1: Participants with obesity or overweight with at least 1 weight-related comorbidity, without type 2 diabetes. J2A-MC-GZP2: Participants with obesity or overweight with type 2 diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2025-521098-14-00

Acronym

J2A-MC-GZPO

Enrollment

198

Registered

2025-07-23

Start date

2025-08-15

Completion date

Unknown

Last updated

2026-01-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes

Brief summary

(GZPO) Number of Participants Allocated to Each Study [Time Frame: Baseline to Week 4], (GZP1) Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 40], (GZP2) Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 40]

Interventions

DRUGOrforglipron

DRUGPlacebo to match LY

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
(GZPO) Number of Participants Allocated to Each Study [Time Frame: Baseline to Week 4], (GZP1) Percent Change from Baseline in Body Weight [Time Frame: Baseline, Week 40], (GZP2) Change from Baseline in Hemoglobin A1c (HbA1c) [Time Frame: Baseline, Week 40]	—

Countries

Czechia, Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026